Literature DB >> 22431923

The brain microenvironment preferentially enhances the radioresistance of CD133(+) glioblastoma stem-like cells.

Muhammad Jamal1, Barbara H Rath, Patricia S Tsang, Kevin Camphausen, Philip J Tofilon.   

Abstract

Brain tumor xenografts initiated from glioblastoma (GBM) CD133(+) tumor stem-like cells (TSCs) are composed of TSC and non-TSC subpopulations, simulating the phenotypic heterogeneity of GBMs in situ. Given that the discrepancies between the radiosensitivity of GBM cells in vitro and the treatment response of patients suggest a role for the microenvironment in GBM radioresistance, we compared the response of TSCs and non-TSCs irradiated under in vitro and orthotopic conditions. As a measure of radioresponse determined at the individual cell level, γH2AX and 53BP1 foci were quantified in CD133(+) cells and their differentiated (CD133(-)) progeny. Under in vitro conditions, no difference was detected between CD133(+) and CD133(-) cells in foci induction or dispersal after irradiation. However, irradiation of orthotopic xenografts initiated from TSCs resulted in the induction of fewer γH2AX and 53BP1 foci in CD133(+) cells compared to their CD133(-) counterparts within the same tumor. Xenograft irradiation resulted in a tumor growth delay of approximately 7 days with a corresponding increase in the percentage of CD133(+) cells at 7 days after radiation, which persisted to the onset of neurologic symptoms. These results suggest that, although the radioresponse of TSCs and non-TSCs does not differ under in vitro growth conditions, CD133(+) cells are relatively radioresistant under intracerebral growth conditions. Whereas these findings are consistent with the suspected role for TSCs as a determinant of GBM radioresistance, these data also illustrate the dependence of the cellular radioresistance on the brain microenvironment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22431923      PMCID: PMC3306260          DOI: 10.1593/neo.111794

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  28 in total

Review 1.  DNA damage and repair in individual cells: applications of the comet assay in radiobiology.

Authors:  P L Olive
Journal:  Int J Radiat Biol       Date:  1999-04       Impact factor: 2.694

2.  DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139.

Authors:  E P Rogakou; D R Pilch; A H Orr; V S Ivanova; W M Bonner
Journal:  J Biol Chem       Date:  1998-03-06       Impact factor: 5.157

3.  Phosphorylated histone H2AX in relation to cell survival in tumor cells and xenografts exposed to single and fractionated doses of X-rays.

Authors:  Dmitry Klokov; Susan M MacPhail; Judit P Banáth; James P Byrne; Peggy L Olive
Journal:  Radiother Oncol       Date:  2006-08-14       Impact factor: 6.280

4.  Histone H2AX phosphorylation is dispensable for the initial recognition of DNA breaks.

Authors:  Arkady Celeste; Oscar Fernandez-Capetillo; Michael J Kruhlak; Duane R Pilch; David W Staudt; Alicia Lee; Robert F Bonner; William M Bonner; André Nussenzweig
Journal:  Nat Cell Biol       Date:  2003-07       Impact factor: 28.824

5.  Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy.

Authors:  June L Chan; Susan W Lee; Benedick A Fraass; Daniel P Normolle; Harry S Greenberg; Larry R Junck; Stephen S Gebarski; Howard M Sandler
Journal:  J Clin Oncol       Date:  2002-03-15       Impact factor: 44.544

6.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

7.  Assumptions in the radiotherapy of glioblastoma.

Authors:  F H Hochberg; A Pruitt
Journal:  Neurology       Date:  1980-09       Impact factor: 9.910

8.  Radiation sensitivity, H2AX phosphorylation, and kinetics of repair of DNA strand breaks in irradiated cervical cancer cell lines.

Authors:  Judit P Banáth; Susan H Macphail; Peggy L Olive
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 12.701

9.  Identification of human brain tumour initiating cells.

Authors:  Sheila K Singh; Cynthia Hawkins; Ian D Clarke; Jeremy A Squire; Jane Bayani; Takuichiro Hide; R Mark Henkelman; Michael D Cusimano; Peter B Dirks
Journal:  Nature       Date:  2004-11-18       Impact factor: 49.962

10.  p53 binding protein 1 (53BP1) is an early participant in the cellular response to DNA double-strand breaks.

Authors:  L B Schultz; N H Chehab; A Malikzay; T D Halazonetis
Journal:  J Cell Biol       Date:  2000-12-25       Impact factor: 10.539

View more
  64 in total

1.  Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma.

Authors:  Krishna P L Bhat; Veerakumar Balasubramaniyan; Brian Vaillant; Ravesanker Ezhilarasan; Howard Colman; Erik P Sulman; Kenneth Aldape; Karlijn Hummelink; Faith Hollingsworth; Khalida Wani; Lindsey Heathcock; Johanna D James; Lindsey D Goodman; Siobhan Conroy; Lihong Long; Nina Lelic; Suzhen Wang; Joy Gumin; Divya Raj; Yoshinori Kodama; Aditya Raghunathan; Adriana Olar; Kaushal Joshi; Christopher E Pelloski; Amy Heimberger; Se Hoon Kim; Daniel P Cahill; Ganesh Rao; Wilfred F A Den Dunnen; Hendrikus W G M Boddeke; Heidi S Phillips; Ichiro Nakano; Frederick F Lang
Journal:  Cancer Cell       Date:  2013-08-29       Impact factor: 31.743

2.  Radiation Drives the Evolution of Orthotopic Xenografts Initiated from Glioblastoma Stem-like Cells.

Authors:  Joseph H McAbee; Barbara H Rath; Kristin Valdez; Dejauwne L Young; Xiaolin Wu; Uma T Shankavaram; Kevin Camphausen; Philip J Tofilon
Journal:  Cancer Res       Date:  2019-10-15       Impact factor: 12.701

3.  The Olfactory Bulb Provides a Radioresistant Niche for Glioblastoma Cells.

Authors:  Cindy R Timme; Charlotte Degorre-Kerbaul; Joseph H McAbee; Barbara H Rath; Xiaolin Wu; Kevin Camphausen; Philip J Tofilon
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-01-25       Impact factor: 7.038

Review 4.  K+ channel signaling in irradiated tumor cells.

Authors:  Benjamin Stegen; Lukas Klumpp; Milan Misovic; Lena Edalat; Marita Eckert; Dominik Klumpp; Peter Ruth; Stephan M Huber
Journal:  Eur Biophys J       Date:  2016-05-10       Impact factor: 1.733

5.  Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells.

Authors:  M Venere; P Hamerlik; Q Wu; R D Rasmussen; L A Song; A Vasanji; N Tenley; W A Flavahan; A B Hjelmeland; J Bartek; J N Rich
Journal:  Cell Death Differ       Date:  2013-10-11       Impact factor: 15.828

6.  Cancer subclonal genetic architecture as a key to personalized medicine.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

7.  Cancer stem cells in glioma: challenges and opportunities.

Authors:  Jialiang Wang; Yufang Ma; Michael K Cooper
Journal:  Transl Cancer Res       Date:  2013-10-01       Impact factor: 1.241

Review 8.  DNA Damage Response Assessments in Human Tumor Samples Provide Functional Biomarkers of Radiosensitivity.

Authors:  Henning Willers; Liliana Gheorghiu; Qi Liu; Jason A Efstathiou; Lori J Wirth; Mechthild Krause; Cläre von Neubeck
Journal:  Semin Radiat Oncol       Date:  2015-05-14       Impact factor: 5.934

9.  The DNA-PK Inhibitor VX-984 Enhances the Radiosensitivity of Glioblastoma Cells Grown In Vitro and as Orthotopic Xenografts.

Authors:  Cindy R Timme; Barbara H Rath; John W O'Neill; Kevin Camphausen; Philip J Tofilon
Journal:  Mol Cancer Ther       Date:  2018-03-16       Impact factor: 6.261

10.  Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells.

Authors:  Robin G Lerner; Stefan Grossauer; Banafsheh Kadkhodaei; Ian Meyers; Maxim Sidorov; Katharina Koeck; Rintaro Hashizume; Tomoko Ozawa; Joanna J Phillips; Mitchel S Berger; Theodore Nicolaides; C David James; Claudia K Petritsch
Journal:  Cancer Res       Date:  2015-11-16       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.